Phenotypes associated with this allele

• Allele Symbol: Tg(MMTV-Erbb2)1Pv
• Allele Name: transgene insertion 1, Paolo Vezzoni
• Allele ID: MGI:3039042
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Map2k7^tm1.1Twad/Map2k7^tm1.2Twad Tg(MMTV-cre)4Mam/0 Tg(MMTV-Erbb2)1Pv/0	involves: 129P2/OlaHsd * C57BL/6 * CD-1 * DBA * FVB/N	MGI:4948967
cx2	Stat3^tm4Vpo/Stat3^tm4Vpo Tg(MMTV-Erbb2)1Pv/0	involves: 129P2/OlaHsd * BALB/cAn * C57BL/6 * CD-1 * DBA	MGI:4438062
tg3	Tg(MMTV-Erbb2)1Pv/0	involves: BALB/c * C57BL/6 * CD-1 * DBA	MGI:5796560

Genotype
MGI:4948967

cn1

• Allelic Composition: Map2k7^tm1.1Twad/Map2k7^tm1.2Twad; Tg(MMTV-cre)4Mam/0; Tg(MMTV-Erbb2)1Pv/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CD-1 * DBA * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:170904 )

• compared with control mice

neoplasm

increased mammary gland tumor incidence ( J:170904 )

• mammary gland tumor onset is earlier and tumor burden heavier than in Tg(MMTV-Erbb2)1Pv mice

increased mammary adenocarcinoma incidence ( J:170904 )

integument

increased mammary gland tumor incidence ( J:170904 )

• mammary gland tumor onset is earlier and tumor burden heavier than in Tg(MMTV-Erbb2)1Pv mice

increased mammary adenocarcinoma incidence ( J:170904 )

mammary gland hyperplasia ( J:170904 )

♀

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:170904 )

• mammary gland tumor onset is earlier and tumor burden heavier than in Tg(MMTV-Erbb2)1Pv mice

increased mammary adenocarcinoma incidence ( J:170904 )

mammary gland hyperplasia ( J:170904 )

♀

Genotype
MGI:4438062

cx2

• Allelic Composition: Stat3^tm4Vpo/Stat3^tm4Vpo; Tg(MMTV-Erbb2)1Pv/0
• Genetic Background: involves: 129P2/OlaHsd * BALB/cAn * C57BL/6 * CD-1 * DBA

neoplasm

increased mammary gland tumor incidence ( J:157976 )

• mice develop palpable tumors significantly earlier than their littermate controls only carrying the transgene

• the presence of larger, more diffused and advanced neoplastic lesions in whole mount mammary gland preparations performed at 7, 12, and 17 weeks of age than their littermate controls only carrying the transgene

• normal proliferation rates in tumor lesions as assessed by PCNA staining

increased mammary adenocarcinoma incidence ( J:157976 )

• invasive carcinomas at 12 weeks

• tumor cells group in solid masses with small aggregates invading the surrounding fibroadipose tissue

• only atypical hyperplastic foci and few in situ carcinomas in the littermate controls only carrying the transgene

increased metastatic potential ( J:157976 )

• strongly enhanced Matrigel invasion potential in cell lines derived from tumors in mutant mice

• strongly enhanced metastatic potential, producing more and faster growing lung metastases both at 5 and 3 weeks when injected into nude mice

increased tumor growth/size ( J:157976 )

• produce tumors faster in nude mice, reaching a diameter of 10 mm 5 weeks after injection of the cell lines derived from tumors in mutant mice

• tumors produced by injection of the cell lines derived from tumors in transgene control mice grow much slower and never reach the 10-mm size

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:157976 )

• mice develop palpable tumors significantly earlier than their littermate controls only carrying the transgene

• the presence of larger, more diffused and advanced neoplastic lesions in whole mount mammary gland preparations performed at 7, 12, and 17 weeks of age than their littermate controls only carrying the transgene

• normal proliferation rates in tumor lesions as assessed by PCNA staining

increased mammary adenocarcinoma incidence ( J:157976 )

• invasive carcinomas at 12 weeks

• tumor cells group in solid masses with small aggregates invading the surrounding fibroadipose tissue

• only atypical hyperplastic foci and few in situ carcinomas in the littermate controls only carrying the transgene

cellular

abnormal actin cytoskeleton morphology ( J:157976 )

• absence of cortical actin and presence of actin stress fibers in cell lines derived from tumors in mutant mice

abnormal cell adhesion ( J:157976 )

• discontinuous E-cadherin, beta-catenin, and Zo-1 distribution in cell lines derived from tumors in mutant mice

decreased apoptosis ( J:157976 )

• reduced TUNEL-positive apoptotic nuclei in tumor lesions

abnormal cell migration ( J:157976 )

• increased migration (>2 fold) in cell lines derived from tumors in mutant mice

integument

increased mammary gland tumor incidence ( J:157976 )

• mice develop palpable tumors significantly earlier than their littermate controls only carrying the transgene

• the presence of larger, more diffused and advanced neoplastic lesions in whole mount mammary gland preparations performed at 7, 12, and 17 weeks of age than their littermate controls only carrying the transgene

• normal proliferation rates in tumor lesions as assessed by PCNA staining

increased mammary adenocarcinoma incidence ( J:157976 )

• invasive carcinomas at 12 weeks

• tumor cells group in solid masses with small aggregates invading the surrounding fibroadipose tissue

• only atypical hyperplastic foci and few in situ carcinomas in the littermate controls only carrying the transgene

Genotype
MGI:5796560

tg3

• Allelic Composition: Tg(MMTV-Erbb2)1Pv/0
• Genetic Background: involves: BALB/c * C57BL/6 * CD-1 * DBA

neoplasm

increased mammary adenocarcinoma incidence ( J:234420 )

♀ • at 5-7 weeks of age, about 30% of mice exhibit mammary gland hyperplasia, from 8-13 weeks of age, 41% of mammary glands show atypical hyperplasia, features of carcinoma in situ are first seen at 14 weeks (9%) and progressively increase to 15% at 22-28 weeks, and invasive breast cancer (ductal breast adenocarcinoma) appears from week 22 and occupies 30% of the mammary glands

♀ • microvessel density markedly increase with mammary gland tumor progression from simple to atypical hyperplasia

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:234420 )

♀ • at 5-7 weeks of age, about 30% of mice exhibit mammary gland hyperplasia, from 8-13 weeks of age, 41% of mammary glands show atypical hyperplasia, features of carcinoma in situ are first seen at 14 weeks (9%) and progressively increase to 15% at 22-28 weeks, and invasive breast cancer (ductal breast adenocarcinoma) appears from week 22 and occupies 30% of the mammary glands

♀ • microvessel density markedly increase with mammary gland tumor progression from simple to atypical hyperplasia

integument

increased mammary adenocarcinoma incidence ( J:234420 )

♀ • at 5-7 weeks of age, about 30% of mice exhibit mammary gland hyperplasia, from 8-13 weeks of age, 41% of mammary glands show atypical hyperplasia, features of carcinoma in situ are first seen at 14 weeks (9%) and progressively increase to 15% at 22-28 weeks, and invasive breast cancer (ductal breast adenocarcinoma) appears from week 22 and occupies 30% of the mammary glands

♀ • microvessel density markedly increase with mammary gland tumor progression from simple to atypical hyperplasia

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:234420